In addition, pricing data for injection pens were less transparent than the available information on the manufacturing cost of semaglutides active pharmaceutical ingredient
"Unsustainable burden" Blue Cross Blue Shield said in 2024, five GLP-1 drug companies accounted for 20% of their total pharmacy spend which topped $300 million last year
Max Manoukian: [00:04:03] These are half ton bins, so, you know, 100, 102 bins
High-throughput, quantitative assessment of the effects of low-dose silica nanoparticles on lung cells: grasping complex toxicity with a great depth of field
Phase 2 Data: The Evidence That Set Expectations The Phase 2 trial of retatrutide in adults with obesity, published in The New England Journal of Medicine in 2023, enrolled 338 participants across multiple dose cohorts and a placebo arm over 48 weeks [1]